Bruno Cassinat

List of Publications by Year
in descending order

176 papers	6,452 citations	70961 41 h-index	71532 76 g-index
178 all docs	178 docs citations	178 times ranked	7166 citing authors

#	Article	IF	Citations
1	Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 2008, 112, 3065-3072.	0.6	511
2	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood, 2008, 111, 4922-4929.	0.6	319
3	DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia. New England Journal of Medicine, 2005, 352, 1529-1538.	13.9	262
4	Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2003, 14, 1889-1896.	3.0	257
5	Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2. Transplantation, 2003, 76, 1233-1235.	0.5	257
6	High molecular response rate of polycythemia vera patients treated with pegylated interferon Â-2a. Blood, 2006, 108, 2037-2040.	0.6	240
7	Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood, 2004, 103, 4119-4125.	0.6	187
8	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nature Genetics, 2015, 47, 1334-1340.	9.4	152
9	Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrology Dialysis Transplantation, 2003, 18, 2409-2414.	0.4	149
10	Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2003, 21, 2326-2334.	0.8	146
11	Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia, 2005, 19, 1153-1160.	3.3	134
12	Clinical and molecular response to interferon-Î± therapy in essential thrombocythemia patients with CALR mutations. Blood, 2015, 126, 2585-2591.	0.6	127
13	Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. Journal of Medical Genetics, 2010, 47, 686-691.	1.5	125
14	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood, 2019, 133, 2233-2242.	0.6	121
15	Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia, 2000, 14, 324-328.	3.3	116
16	Juvenile myelomonocytic leukaemia and Noonan syndrome. Journal of Medical Genetics, 2014, 51, 689-697.	1.5	112
17	Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia, 2016, 30, 776-781.	3.3	109
18	Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporineâ€“sirolimus interaction. Kidney International, 2006, 70, 1019-1025.	2.6	102

#	Article	IF	Citations
19	Synergistic effects of PRIMA-1^{Met} (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 2020, 105, 1539-1551.	1.7	101
20	Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood, 2009, 113, 412-421.	0.6	97
21	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 2013, 27, 2032-2039.	3.3	96
22	The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, 2006, 20, 1319-1321.	3.3	92
23	JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood, 2013, 121, 658-665.	0.6	88
24	The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia, 2017, 31, 1661-1670.	3.3	83
25	Clonal analysis of erythroid progenitors suggests that pegylated interferon Î±-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia, 2010, 24, 1519-1523.	3.3	79
26	Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica, 2009, 94, 487-495.	1.7	77
27	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia, 2015, 29, 1084-1091.	3.3	70
28	Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1206-1211.	2.0	70
29	Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia. New England Journal of Medicine, 2014, 371, 188-189.	13.9	67
30	Development of a Realâ€Time Polymeraseâ€Chainâ€Reaction Assay for Quantitative Detection ofEnterocytozoon bieneusiDNA in Stool Specimens from Immunocompromised Patients with Intestinal Microsporidiosis. Journal of Infectious Diseases, 2003, 187, 1469-1474.	1.9	64
31	Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 460-468.	1.2	64
32	Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features. Thrombosis and Haemostasis, 2018, 118, 1586-1599.	1.8	60
33	Development of a Real-Time PCR Assay for Quantitative Detection of Encephalitozoon intestinalis DNA. Journal of Clinical Microbiology, 2003, 41, 1410-1413.	1.8	51
34	Expression level and differential JAK2-V617Fâ€“binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood, 2010, 116, 5961-5971.	0.6	51
35	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	1.8	50
36	Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc. Blood, 2013, 122, 306-306.	0.6	50

#	Article	IF	Citations
37	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group. Journal of Clinical Oncology, 2012, 30, 1641-1646.	0.8	49
38	Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Advances, 2021, 5, 1442-1451.	2.5	48
39	Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. Cellular Signalling, 2012, 24, 2369-2377.	1.7	47
40	Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia, 2006, 20, 1181-1183.	3.3	45
41	Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica, 2013, 98, 1517-1524.	1.7	45
42	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. Leukemia Research, 2011, 35, 863-867.	0.4	44
43	Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?. Leukemia, 2008, 22, 452-453.	3.3	41
44	In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood, 2001, 98, 2862-2864.	0.6	36
45	Epigenetic patterns of the retinoic acid receptor Î²2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene, 2007, 26, 4018-4024.	2.6	36
46	Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nature Communications, 2018, 9, 2047.	5.8	35
47	Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer Journal, 2018, 8, 94.	2.8	34
48	Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood, 2007, 109, 4450-4460.	0.6	33
49	Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. European Journal of Cancer, 2007, 43, 816-821.	1.3	31
50	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances, 2020, 4, 3708-3715.	2.5	31
51	Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood, 2002, 99, 2615-2616.	0.6	30
52	Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register. Leukemia, 2004, 18, 1553-1555.	3.3	30
53	Longâ€term followâ€up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology, 2013, 88, 556-559.	2.0	30
54	Quantification of the Mutant CALR Allelic Burden by Digital PCR. Journal of Molecular Diagnostics, 2016, 18, 68-74.	1.2	30

#	Article	IF	Citations
55	Bexarotene via CBP/p300 Induces Suppression of NF-ÎºBâ€“Dependent Cell Growth and Invasion in Thyroid Cancer. Clinical Cancer Research, 2012, 18, 442-453.	3.2	28
56	Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients. PLoS ONE, 2010, 5, e8893.	1.1	27
57	Sequence Analysis Identifies TTRAP, a Protein That Associates with CD40 and TNF Receptor-Associated Factors, as a Member of a Superfamily of Divalent Cation-Dependent Phosphodiesterases. Biochemical and Biophysical Research Communications, 2001, 285, 1274-1279.	1.0	26
58	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. International Immunopharmacology, 2016, 40, 466-473.	1.7	25
59	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNÎ± in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	0.6	25
60	HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia, 2008, 22, 578-584.	3.3	24
61	Mutations in exon 12 of JAK2 are mainly found in JAK2 V617Fâ€negative polycythaemia vera patients. British Journal of Haematology, 2008, 142, 676-679.	1.2	24
62	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. European Journal of Cancer, 2014, 50, 1159-1168.	1.3	24
63	Identification of JAK2 mutations in canine primary polycythemia. Experimental Hematology, 2011, 39, 542-545.	0.2	23
64	New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor Î± Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation. Molecular and Cellular Biology, 2011, 31, 1409-1418.	1.1	23
65	In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. Leukemia, 2013, 27, 2404-2407.	3.3	23
66	Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. Blood, 2019, 133, 1766-1777.	0.6	23
67	Impact of NFE2 mutations on AML transformation andÂoverall survival in patients with myeloproliferative neoplasms. Blood, 2021, 138, 2142-2148.	0.6	23
68	From guidelines to hospital practice: reducing inappropriate ordering of thyroid hormone and antibody tests. European Journal of Endocrinology, 2000, 142, 605-610.	1.9	22
69	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Journal of Experimental Medicine, 2021, 218, .	4.2	22
70	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744.	2.5	21
71	The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thrombosis and Haemostasis, 2008, 99, 1119-1120.	1.8	20
72	Reduced intensity hematopoietic stem cell transplantation forÂaccelerated-phase myelofibrosis. Blood Advances, 2022, 6, 1222-1231.	2.5	20

#	Article	IF	Citations
73	Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2011, 46, 557-561.	1.3	19
74	Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent. Leukemia, 2015, 29, 2277-2284.	3.3	19
75	Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transplantation, 2021, 56, 1888-1899.	1.3	18
76	Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2RÎ³â^'/â^' mice. Leukemia, 2012, 26, 2432-2435.	3.3	17
77	PMLâ€"RARÎ± ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL. Leukemia, 2010, 24, 473-476.	3.3	16
78	Neurological disorders in essential thrombocythemia. Haematologica, 2011, 96, 1866-1869.	1.7	16
79	Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls. Annals of Hematology, 2019, 98, 111-118.	0.8	16
80	MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491. Blood, 2020, 135, 948-953.	0.6	16
81	Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission. Blood, 2020, 136, 35-36.	0.6	16
82	Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management. Oncogene, 2001, 20, 7154-7160.	2.6	15
83	Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses. Haematologica, 2020, 105, e95-e97.	1.7	15
84	Comparison of antibiotic combinations against penicillin-resistant pneumococci. Journal of Antimicrobial Chemotherapy, 1994, 34, 785-790.	1.3	14
85	A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation. Cancer Genetics and Cytogenetics, 2005, 159, 69-73.	1.0	14
86	When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). Leukemia Research, 2009, 33, 1178-1182.	0.4	14
87	Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET. Journal of Nuclear Medicine, 2017, 58, 1603-1608.	2.8	14
88	Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia, 2020, 34, 1658-1668.	3.3	14
89	The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood, 2011, 117, 5777-5778.	0.6	13
90	Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms. Blood, 2014, 123, 794-796.	0.6	13

#	Article	IF	Citations
91	Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. European Journal of Immunology, 1995, 25, 2661-2667.	1.6	12
92	Co-expression and secretion of C3, the third component of complement and a C3-cleaving cysteine proteinase in a highly metastatic human melanoma cell line. Immunology Letters, 1997, 58, 107-112.	1.1	12
93	Overcoming bacterial DNA contamination in real-time PCR and RT-PCR reactions for LacZ detection in cell therapy monitoring. Molecular and Cellular Probes, 2004, 18, 437-441.	0.9	12
94	Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNÎ± treatment. Leukemia, 2014, 28, 460-463.	3.3	12
95	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. European Journal of Haematology, 2019, 103, 552-557.	1.1	12
96	Inhibitory Activity of Human Immunodeficiency Virus Aspartyl Protease Inhibitors against Encephalitozoon intestinalis Evaluated by Cell Culture-Quantitative PCR Assay. Antimicrobial Agents and Chemotherapy, 2005, 49, 2362-2366.	1.4	11
97	Impact of hydroxycarbamide and interferon-Î± on red cell adhesion and membrane protein expression in polycythemia vera. Haematologica, 2018, 103, 972-981.	1.7	11
98	Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood, 2020, 135, 1032-1043.	0.6	11
99	Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2^{V617F} mutation. Haematologica, 2017, 102, e241-e244.	1.7	10
100	Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms. Cancers, 2020, 12, 992.	1.7	10
101	Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia, 2021, 35, 871-875.	3.3	10
102	Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number. Blood Cancer Journal, 2012, 2, e66-e66.	2.8	9
103	Quantification of JAK2V617F mutation by next-generation sequencing technology. American Journal of Hematology, 2013, 88, 536-537.	2.0	9
104	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. Biology of Blood and Marrow Transplantation, 2020, 26, 1160-1170.	2.0	9
105	New chimeric RNAs in acute myeloid leukemia. F1000Research, 2017, 6, 1302.	0.8	9
106	Pitfalls in CALR exon 9 mutation detection: A singleâ€center experience in 571 positive patients. International Journal of Laboratory Hematology, 2020, 42, 827-832.	0.7	8
107	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.. Blood, 2006, 108, 377-377.	0.6	8
108	Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon Î±-2a (peg-IFNÎ±-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial. Blood, 2011, 118, 280-280.	0.6	8

#	Article	IF	Citations
109	New chimeric RNAs in acute myeloid leukemia. F1000Research, 2017, 6, 1302.	0.8	8
110	Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2. Molecular Immunology, 1995, 32, 1295-1298.	1.0	7
111	Tracking the extramedullary PML-RARÎ±-positive cell reservoirs in a preclinical model: Biomarker of long-term drug efficacy. Molecular and Cellular Probes, 2013, 27, 1-5.	0.9	7
112	Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Advances, 2022, 6, 2813-2823.	2.5	7
113	Lu/BCAMâ€mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients. American Journal of Hematology, 2015, 90, E137-8.	2.0	6
114	Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 689-689.	0.6	6
115	Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis. Cells, 2022, 11, 49.	1.8	6
116	Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Blood, 2005, 105, 3743-3745.	0.6	5
117	Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. Leukemia Research, 2013, 37, 312-319.	0.4	5
118	Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm. Thrombosis Research, 2015, 136, 839-840.	0.8	5
119	CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. Haematologica, 2021, 106, 863-864.	1.7	5
120	Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements. Haematologica, 2021, 106, 1167-1171.	1.7	5
121	Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 251-252.	1.8	5
122	Familial Essential Thrombocythemia Among Qatari Tribes. Blood, 2013, 122, 5244-5244.	0.6	5
123	Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?. Blood Cancer Journal, 2012, 2, e70-e70.	2.8	4
124	Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone. Leukemia and Lymphoma, 2017, 58, 749-751.	0.6	4
125	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia, 2018, 32, 2066-2069.	3.3	4
126	The Challenge of Diagnosing Fanconi Anemia in Patients with Bone Marrow Failure (BMF): A Study in 82 BMF Patients.. Blood, 2006, 108, 991-991.	0.6	4

#	Article	IF	Citations
127	SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). Blood, 2020, 136, 1-1.	0.6	4
128	Auer rods and differentiation in acute promyelocytic leukemia. British Journal of Haematology, 2008, 142, 998-1000.	1.2	3
129	Unexplained thrombocytosis: association of Baltimore polymorphism with germline <scp>MPL</scp> nonsense mutation. British Journal of Haematology, 2016, 175, 167-169.	1.2	3
130	How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?. Expert Review of Hematology, 2019, 12, 473-476.	1.0	3
131	International external quality assurance of JAK2 V617F quantification. Annals of Hematology, 2019, 98, 1111-1118.	0.8	3
132	ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis. International Journal of Molecular Sciences, 2021, 22, 3530.	1.8	3
133	Revisiting Diagnostic performances of serum erythropoÃ¯etin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement. British Journal of Haematology, 2022, 196, 676-680.	1.2	3
134	Future perspectives for acute promyelocytic leukemia therapy. Seminars in Hematology, 2001, 38, 86-91.	1.8	3
135	Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis. Blood, 2021, 138, 317-317.	0.6	3
136	Future perspectives for acute promyelocytic leukemia therapy. Seminars in Hematology, 2001, 38, 86-91.	1.8	2
137	Dosage du 27â€“29 sur AIA 600 IIÂ® Tosoh-BioscienceÂ: Ã‰valuation analytique et comparaison avec le dosage de CA 15-3 KryptorÂ® (Brahms). Immuno-Analyse Et Biologie Specialisee, 2002, 17, 401-406.	0.0	2
138	In vitro assessment of the sensitivity to APRâ€246Â+Âazacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients. British Journal of Haematology, 2021, 194, e77-e79.	1.2	2
139	Analysis of JAK2 Mutation in Essential Thrombocythemia (ET) Patients with Monoclonal and Polyclonal X-Chromosome Inactivation Patterns (XCIPs).. Blood, 2005, 106, 2603-2603.	0.6	2
140	All Trans Retinoic Acid (atRA) Differentiation Markers in Normal and Retinoid-Resistant Acute Promyelocytic Leukemia Cells Revealed Induction of atRA Metabolism as Relevant Prognostic of APL Sensitivity to Therapy.. Blood, 2005, 106, 3256-3256.	0.6	2
141	Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study. Blood, 2011, 118, 2812-2812.	0.6	2
142	Targeted Exome Sequencing Identifies Novel Mutations in Familial Myeloproliferative Neoplasms Patients in the State of Qatar. Blood, 2014, 124, 5570-5570.	0.6	2
143	Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French Experience. HemaSphere, 2021, 5, e658.	1.2	2
144	Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF). Blood, 2020, 136, 8-8.	0.6	2

#	Article	IF	Citations
145	Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient. American Journal of Hematology, 2012, 87, 646-646.	2.0	1
146	<scp>TET</scp>2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis. British Journal of Haematology, 2014, 165, 416-419.	1.2	1
147	When hemolysis masks polycythemia vera. Clinical Case Reports (discontinued), 2019, 7, 438-441.	0.2	1
148	Exome analysis of treatmentâ€related <scp>AML</scp> after <scp>APL</scp> suggests secondary evolution. British Journal of Haematology, 2019, 185, 984-987.	1.2	1
149	Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses. Blood, 2019, 134, 836-836.	0.6	1
150	Treatment of Progression of Myeloproliferative Disorders(MPD) to MDS/AML by Azacytidine (AZA) : A Preliminary Report on 17 Patients (pts). Blood, 2008, 112, 2800-2800.	0.6	1
151	Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis (FLT-MF-2009 Study). Blood, 2014, 124, 3195-3195.	0.6	1
152	Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia. Blood, 2016, 128, 2892-2892.	0.6	1
153	PVN1: A Phase 2 Study of Pegylated Interferon-Î±2a in Polycythemia Vera (PV) by the â€œPV-Nordâ€•Group. Preliminary Report of Efficacy and Safety.. Blood, 2005, 106, 4940-4940.	0.6	1
154	AK2 Regulates Hematopoietic Cell Survival, Proliferation and Differentiation Along the T-Cell and Neutrophil Lineages. Blood, 2011, 118, 1315-1315.	0.6	1
155	Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms. Blood, 2021, 138, 3620-3620.	0.6	1
156	Intermethod discordance for alpha-fetoprotein measurements in Fanconi anemia. Clinical Chemistry, 2001, 47, 1405-9.	1.5	1
157	Response. Leukemia, 2000, 14, 1531-1531.	3.3	0
158	Dosages de NSE et protÃ©ine S-100 dans le liquide cÃ©phalorachidien (LCR). Immuno-Analyse Et Biologie Specialisee, 2002, 17, 407-411.	0.0	0
159	The V617F JAK2 mutation and the increase in platelet CD36 in essential thrombocythemia are unrelated events. European Journal of Haematology, 2007, 79, 269-270.	1.1	0
160	Screening for JAK2V617F and MPL515 Mutations in Idiopathic Pulmonary Fibrosis.. , 2009, , .		0
161	P126 Treatment of progression of myeloproliferative neoplasm (MPN) to MDS/AML by azacytidine (AZA): a report on 44 patients (pts). Leukemia Research, 2009, 33, S132-S133.	0.4	0
162	Live and let (MPN cells) die!. Blood, 2012, 120, 2933-2934.	0.6	0

#	Article	IF	Citations
163	Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S107-S108.	2.0	0
164	The JAK2 V617F Mutation Identifies Specific Subgroups of Myelodysplastic Syndrome (MDS).. Blood, 2006, 108, 2610-2610.	0.6	0
165	Human Adenylate Kinase 2 Deficiency Inhibits Hematopoietic Cell Differentiation towards Neutrophil and T Lymphoid Lineages.. Blood, 2009, 114, 78-78.	0.6	0
166	Lack of Association Between the 46/1 JAK2 Haplotype and the Presence of JAK2V617F Mutation In Splanchnic Vein Thrombosis Patients. Blood, 2010, 116, 4120-4120.	0.6	0
167	AOP2014/P1101, a Novel Peg-Proline-Interferon Alpha (IFNa) 2b, Specifically Targets JAK2V617F-Positive Polycythemia Vera (PV) Cells. Blood, 2013, 122, 1611-1611.	0.6	0
168	Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?. Blood, 2014, 124, 3200-3200.	0.6	0
169	Establishment of Acute Myeloid Leukemic Xenografts as Preclinical Models of Epigenetic Therapies. International Journal of Hematology Research, 2015, 1, 79-89.	0.2	0
170	Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins. PLoS ONE, 2015, 10, e0129222.	1.1	0
171	Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. Blood, 2016, 128, 2861-2861.	0.6	0
172	Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms. Blood, 2016, 128, 1941-1941.	0.6	0
173	JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics. Blood, 2016, 128, 4273-4273.	0.6	0
174	Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation. Blood, 2016, 128, 3106-3106.	0.6	0
175	S1610ÂMASKED POLYCYTHEMIA VERA: ANALYSIS OF A SINGLE CENTER SERIES OF 2480 RED CELL MASSES.. HemaSphere, 2019, 3, 742.	1.2	0
176	JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators. Blood, 2020, 136, 4-5.	0.6	0